{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:25:11Z","timestamp":1790990711847,"version":"4.1.0"},"reference-count":46,"publisher":"Keio Journal of Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Keio J. Med.","Keio j. med"],"published-print":{"date-parts":[[2025]]},"DOI":"10.2302\/kjm.2023-0013-ir","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T22:27:15Z","timestamp":1693002435000},"page":"37-41","source":"Crossref","is-referenced-by-count":12,"title":["Neurofibromatosis 1 (von Recklinghausen Disease)"],"prefix":"10.2302","volume":"74","author":[{"given":"Yuichi","family":"Yoshida","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine of Sensory and Motor              Organs, Faculty of Medicine, Tottori University, Yonago,            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1082","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wilson BN, John AM, Handler MZ, Schwartz RA:          Neurofibromatosis type 1: new developments in genetics and treatment. J Am Acad Dermatol          2021; 84: 1667\u20131676. PMID:32771543          https:\/\/doi.org\/10.1016\/j.jaad.2020.07.105","DOI":"10.1016\/j.jaad.2020.07.105"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Viskochil D, Buchberg AM, Xu G, Cawthon RM,          Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA, White R, O\u2019Connell P:          Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1          locus. Cell 1990; 62: 187\u2013192. PMID:1694727          https:\/\/doi.org\/10.1016\/0092-8674(90)90252-A","DOI":"10.1016\/0092-8674(90)90252-A"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lammert M, Friedman JM, Kluwe L, Mautner VF:          Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch          Dermatol 2005; 141: 71\u201374. PMID:15655144          https:\/\/doi.org\/10.1001\/archderm.141.1.71","DOI":"10.1001\/archderm.141.1.71"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yoshida Y, Ehara Y, Koga M, Imafuku S, Yamamoto          O: Epidemiological analysis of major complications requiring medical intervention in          patients with neurofibromatosis 1. Acta Derm Venereol 2018; 98: 753\u2013756. PMID:29796689          https:\/\/doi.org\/10.2340\/00015555-2975","DOI":"10.2340\/00015555-2975"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tanito K, Ota A, Kamide R, Nakagawa H, Niimura M:          Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1. J Dermatol          2014; 41: 724\u2013728. PMID:25041723 https:\/\/doi.org\/10.1111\/1346-8138.12567","DOI":"10.1111\/1346-8138.12567"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tinschert S, Naumann I, Stegmann E, Buske A,          Kaufmann D, Thiel G, Jenne DE: Segmental neurofibromatosis is caused by somatic mutation          of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000; 8: 455\u2013459.          PMID:10878667 https:\/\/doi.org\/10.1038\/sj.ejhg.5200493","DOI":"10.1038\/sj.ejhg.5200493"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ruggieri M, Huson SM: The clinical and diagnostic          implications of mosaicism in the neurofibromatoses. Neurology 2001; 56: 1433\u20131443.          PMID:11409413 https:\/\/doi.org\/10.1212\/WNL.56.11.1433","DOI":"10.1212\/WNL.56.11.1433"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Walker L, Thompson D, Easton D, Ponder B, Ponder          M, Frayling I, Baralle D: A prospective study of neurofibromatosis type 1 cancer incidence          in the UK. Br J Cancer 2006; 95: 233\u2013238. PMID:16786042          https:\/\/doi.org\/10.1038\/sj.bjc.6603227","DOI":"10.1038\/sj.bjc.6603227"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rasmussen SA, Yang Q, Friedman JM: Mortality in          neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001; 68:          1110\u20131118. PMID:11283797 https:\/\/doi.org\/10.1086\/320121","DOI":"10.1086\/320121"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yoshida Y, Ehara Y, Koga M, Imafuku S:          Health\u2010related quality of life in patients with neurofibromatosis 1 in Japan: a          questionnaire survey using EQ\u20105D\u20105L. J Dermatol 2022; 49: 1228\u20131232. PMID:35781730          https:\/\/doi.org\/10.1111\/1346-8138.16510","DOI":"10.1111\/1346-8138.16510"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. National Institutes of Health Consensus          Development Conference: Neurofibromatosis. Conference statement. Arch Neurol 1988; 45:          575\u2013578. PMID:3128965          https:\/\/doi.org\/10.1001\/archneur.1988.00520290115023","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw          H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A: Guidelines for the          diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2006; 44:          81\u201388. PMID:17105749 https:\/\/doi.org\/10.1136\/jmg.2006.045906","DOI":"10.1136\/jmg.2006.045906"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. DeBella K, Szudek J, Friedman JM: Use of the          national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.          Pediatrics 2000; 105: 608\u2013614. PMID:10699117          https:\/\/doi.org\/10.1542\/peds.105.3.608","DOI":"10.1542\/peds.105.3.608"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Legius E, Messiaen L, Wolkenstein P, Pancza P,          Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ,          Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA,          Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil          D, Wimmer K, Yohay K,K, Huson SM, Evans DG, Plotkin SR, International Consensus Group on          Neurofibromatosis Diagnostic Criteria (I-NF-DC): Revised diagnostic criteria for          neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.          Genet Med 2021; 23: 1506\u20131513. PMID:34012067          https:\/\/doi.org\/10.1038\/s41436-021-01170-5","DOI":"10.1038\/s41436-021-01170-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ho WY, Farrelly E, Stevenson DA: Evaluation of          the impact of the 2021 revised neurofibromatosis type 1 diagnostic criteria on time to          diagnosis. Am J Med Genet A 2022; 188: 2584\u20132589. PMID:35779212          https:\/\/doi.org\/10.1002\/ajmg.a.62890","DOI":"10.1002\/ajmg.a.62890"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tidyman WE, Rauen KA: The RASopathies:          developmental syndromes of Ras\/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19:          230\u2013236. PMID:19467855 https:\/\/doi.org\/10.1016\/j.gde.2009.04.001","DOI":"10.1016\/j.gde.2009.04.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Brems H, Chmara M, Sahbatou M, Denayer E,          Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P,          Thomas G, Yoshimura A, Legius E: Germline loss-of-function mutations in SPRED1 cause a          neurofibromatosis 1-like phenotype. Nat Genet 2007; 39: 1120\u20131126. PMID:17704776          https:\/\/doi.org\/10.1038\/ng2113","DOI":"10.1038\/ng2113"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gottfried ON, Viskochil DH, Couldwell WT:          Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic          implications. Neurosurg Focus 2010; 28: E8. PMID:20043723          https:\/\/doi.org\/10.3171\/2009.11.FOCUS09221","DOI":"10.3171\/2009.11.FOCUS09221"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koga M, Yoshida Y, Imafuku S: Clinical          characteristics of the halo phenomenon in infants with neurofibromatosis 1: a case series.          Acta Derm Venereol 2018; 98: 153\u2013154. PMID:28902947          https:\/\/doi.org\/10.2340\/00015555-2796","DOI":"10.2340\/00015555-2796"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ehara Y, Yamamoto O, Kosaki K, Yoshida Y: Natural          course and characteristics of cutaneous neurofibromas in neurofibromatosis 1. J Dermatol          2018; 45: 53\u201357. PMID:28891076 https:\/\/doi.org\/10.1111\/1346-8138.14025","DOI":"10.1111\/1346-8138.14025"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ehara Y, Koga M, Imafuku S, Yamamoto O, Yoshida          Y: Distribution of diffuse plexiform neurofibroma on the body surface in patients with          neurofibromatosis 1. J Dermatol 2020; 47: 190\u2013192. PMID:31849109          https:\/\/doi.org\/10.1111\/1346-8138.15194","DOI":"10.1111\/1346-8138.15194"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fisher MJ, Blakeley JO, Weiss BD, Dombi E,          Ahlawat S, Akshintala S, Belzberg AJ, Bornhorst M, Bredella MA, Cai W, Ferner RE, Gross          AM, Harris GJ, Listernick R, Ly I, Martin S, Mautner VF, Salamon JM, Salerno KE, Spinner          RJ, Staedtke V, Ullrich NJ, Upadhyaya M, Wolters PL, Yohay K, Widemann BC: Management of          neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol 2022; 24:          1827\u20131844. PMID:35657359 https:\/\/doi.org\/10.1093\/neuonc\/noac146","DOI":"10.1093\/neuonc\/noac146"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF:          Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;          296: 920\u2013922. PMID:11988578 https:\/\/doi.org\/10.1126\/science.1068452","DOI":"10.1126\/science.1068452"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns          DK, Zhu Y: Induction of abnormal proliferation by nonmyelinating Schwann cells triggers          neurofibroma formation. Cancer Cell 2008; 13: 117\u2013128. PMID:18242512          https:\/\/doi.org\/10.1016\/j.ccr.2008.01.002","DOI":"10.1016\/j.ccr.2008.01.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nguyen R, Dombi E, Widemann BC, Solomon J,          Fuensterer C, Kluwe L, Friedman JM, Mautner VF: Growth dynamics of plexiform          neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.          Orphanet J Rare Dis 2012; 7: 75. PMID:23035791          https:\/\/doi.org\/10.1186\/1750-1172-7-75","DOI":"10.1186\/1750-1172-7-75"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ly KI, Merker VL, Cai W, Bredella MA, Muzikansky          A, Thalheimer RD, Da JL, Orr CC, Herr HP, Morris ME, Chang CY, Harris GJ, Plotkin SR,          Jordan JT: Ten-year follow-up of internal neurofibroma growth behavior in adult patients          with neurofibromatosis type 1 using whole-body MRI. Neurology 2023; 100: e661\u2013e670.          PMID:36332985 https:\/\/doi.org\/10.1212\/WNL.0000000000201535","DOI":"10.1212\/WNL.0000000000201535"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Treglia G, Taralli S, Bertagna F, Salsano M,          Muoio B, Novellis P, Vita ML, Maggi F, Giordano A: Usefulness of whole-body          fluorine-18-fluorodeoxyglucose positron emission tomography in patients with          neurofibromatosis type 1: a systematic review. Radiol Res Pract 2012; 2012: 1\u20139.          PMID:22991664 https:\/\/doi.org\/10.1155\/2012\/431029","DOI":"10.1155\/2012\/431029"},{"key":"28","unstructured":"28. Otsuka F, Kawashima T, Imakado S, Usuki Y,          Hon-Mura S: Lisch nodules and skin manifestation in neurofibromatosis type 1. Arch          Dermatol 2001; 137: 232\u2013233. PMID:11176707"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Alwan S, Tredwell SJ, Friedman JM: Is osseous          dysplasia a primary feature of neurofibromatosis 1 (NF1)? Clin Genet 2005; 67: 378\u2013390.          PMID:15811002 https:\/\/doi.org\/10.1111\/j.1399-0004.2005.00410.x","DOI":"10.1111\/j.1399-0004.2005.00410.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Durrani AA, Crawford AH, Chouhdry SN, Saifuddin          A, Morley TR: Modulation of spinal deformities in patients with neurofibromatosis type 1.          Spine 2000; 25: 69\u201375. PMID:10647163          https:\/\/doi.org\/10.1097\/00007632-200001010-00013","DOI":"10.1097\/00007632-200001010-00013"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Peduto C, Zanobio M, Nigro V, Perrotta S, Piluso          G, Santoro C: Neurofibromatosis type 1: pediatric aspects and review of genotype\u2013phenotype          correlations. Cancers (Basel) 2023; 15: 1217. PMID:36831560          https:\/\/doi.org\/10.3390\/cancers15041217","DOI":"10.3390\/cancers15041217"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yoshida Y, Ehara Y, Kosaki K, Yamamoto O: Large          number of cutaneous neurofibromas beyond age-appropriate incidence in a patient with a          large deletion of NF1. J Dermatol 2018; 45: 363\u2013364. PMID:29498099          https:\/\/doi.org\/10.1111\/1346-8138.14187","DOI":"10.1111\/1346-8138.14187"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Carton C, Evans DG, Blanco I, Friedrich RE,          Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, R\u00f6hl C, Peltonen S, Stivaros S,          Legius E, Oostenbrink R, ERN GENTURIS NF1 Tumour Management Guideline Group: ERN GENTURIS          tumour surveillance guidelines for individuals with neurofibromatosis type 1.          EClinicalMedicine 2023; 56: 101818. PMID:36684394          https:\/\/doi.org\/10.1016\/j.eclinm.2022.101818","DOI":"10.1016\/j.eclinm.2022.101818"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ehara Y, Yamamoto O, Kosaki K, Yoshida Y:          Clinical severity in Japanese patients with neurofibromatosis 1 based on DNB          classification. J Dermatol 2017; 44: 1262\u20131267. PMID:29098729          https:\/\/doi.org\/10.1111\/1346-8138.13902","DOI":"10.1111\/1346-8138.13902"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yoshida Y, Sato N, Furumura M, Nakayama J:          Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed-radio frequency          in combination with topical application of vitamin D3 ointment. J Dermatol 2007; 34:          227\u2013230. PMID:17352718 https:\/\/doi.org\/10.1111\/j.1346-8138.2007.00258.x","DOI":"10.1111\/j.1346-8138.2007.00258.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Cen Q, Gu Y, Luo L, Shang Y, Rao Y, Zhu J, Han Y,          Yu W, Liu Y, Wu X, Ying H, Ma G, Lin X: Comparative effectiveness of 755-nm picosecond          laser, 755- and 532-nm nanosecond lasers for treatment of cafe-au-lait macules (CALMs): a          randomized, split-lesion clinical trial. Lasers Surg Med 2021; 53: 435\u2013442. PMID:32896932          https:\/\/doi.org\/10.1002\/lsm.23316","DOI":"10.1002\/lsm.23316"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Wolkenstein P, Zeller J, Revuz J, Ecosse E,          Lepl\u00e8ge A: Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study          of 128 cases. Arch Dermatol 2001; 137: 1421\u20131425. PMID:11708944          https:\/\/doi.org\/10.1001\/archderm.137.11.1421","DOI":"10.1001\/archderm.137.11.1421"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Onesti MG, Carella S, Spinelli G, Scuderi N: The          megasession technique for excision of multiple neurofibromas. Dermatol Surg 2010; 36:          1488\u20131490. PMID:20636383 https:\/\/doi.org\/10.1111\/j.1524-4725.2010.01666.x","DOI":"10.1111\/j.1524-4725.2010.01666.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Peltonen S, Jannic A, Wolkenstein P: Treatment of          cutaneous neurofibromas with carbon dioxide laser: technique and patient experience. Eur J          Med Genet 2022; 65: 104386. PMID:34768015          https:\/\/doi.org\/10.1016\/j.ejmg.2021.104386","DOI":"10.1016\/j.ejmg.2021.104386"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Yoshida Y, Yamamoto O: Ultrasonic dissection for          diffuse plexiform neurofibroma. Dermatol Surg 2010; 36: 1773\u20131774. PMID:20979341          https:\/\/doi.org\/10.1111\/j.1524-4725.2010.01757.x","DOI":"10.1111\/j.1524-4725.2010.01757.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Rabab\u2019h O, Gharaibeh A, Al-Ramadan A, Ismail M,          Shah J: Pharmacological approaches in neurofibromatosis type 1-associated nervous system          tumors. Cancers (Basel) 2021; 13: 3880. PMID:34359780          https:\/\/doi.org\/10.3390\/cancers13153880","DOI":"10.3390\/cancers13153880"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Gross AM, Wolters PL, Dombi E, Baldwin A,          Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC,          Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C,          Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA,          Widemann BC: Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med          2020; 382: 1430\u20131442. PMID:32187457 https:\/\/doi.org\/10.1056\/NEJMoa1912735","DOI":"10.1056\/NEJMoa1912735"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Gross AM, Dombi E, Wolters PL, Baldwin A, Dufek          A, Herrera K, Martin S, Derdak J, Heisey KS, Whitcomb PM, Steinberg SM, Venzon DJ, Fisher          MJ, Kim A, Bornhorst M, Weiss BD, Blakeley JO, Smith MA, Widemann BC: Long-term safety and          efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for          inoperable plexiform neurofibromas. Neuro Oncol 2023; noad086. PMID:37115514          https:\/\/doi.org\/10.1093\/neuonc\/noad086","DOI":"10.1093\/neuonc\/noad086"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Pemov A, Li H, Presley W, Wallace MR, Miller DT:          Genetics of human malignant peripheral nerve sheath tumors. Neurooncol Adv 2020; 2:          i50\u2013i61. PMID:32642732 https:\/\/doi.org\/10.1093\/noajnl\/vdz049","DOI":"10.1093\/noajnl\/vdz049"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S,          Ligon AH, Lindeman N, Campagne O, Banerjee A, Gururangan S, Kilburn LB, Goldman S,          Qaddoumi I, Baxter P, Vezina G, Bregman C, Patay Z, Jones JY, Stewart CF, Fisher MJ, Doyle          LA, Smith M, Dunkel IJ, Fouladi M: A phase II trial of selumetinib in children with          recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain          Tumor Consortium study. Neuro Oncol 2021; 23: 1777\u20131788. PMID:33631016          https:\/\/doi.org\/10.1093\/neuonc\/noab047","DOI":"10.1093\/neuonc\/noab047"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Nishida Y, Ikuta K, Natsume A, Ishihara N,          Morikawa M, Kidokoro H, Muramatsu Y, Nonobe N, Ishizuka K, Takeichi T, Kanbe M, Mizuno S,          Imagama S, Ozaki N: Establishment of in-hospital clinical network for patients with          neurofibromatosis type 1 in Nagoya University Hospital. Sci Rep 2021; 11: 11933.          PMID:34099792 https:\/\/doi.org\/10.1038\/s41598-021-91345-6","DOI":"10.1038\/s41598-021-91345-6"}],"container-title":["The Keio Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/74\/1\/74_2023-0013-IR\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:03:15Z","timestamp":1743220995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/74\/1\/74_2023-0013-IR\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2302\/kjm.2023-0013-ir","relation":{},"ISSN":["0022-9717","1880-1293"],"issn-type":[{"value":"0022-9717","type":"print"},{"value":"1880-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2023-0013-IR"}}